Codes ATC:
N05CD08
EMLc
Indication
Status epilepticus
Code ICD11:
8A66
INN
Midazolam
Type de médicament
Chemical agent
Type de liste
Liste de base
(EML)
(EMLc)
(EMLc)
Additional notes
Midazolam injection may be used for buccal administration when solution for oromucosal administration is not available.
Formulations
Parenteral > General injections > unspecified:
1 mg per mL in 5 mL vial (for buccal administration) ;
5 mg per mL in 1 mL vial (for buccal administration) ;
5 mg per mL in 3 mL vial (for buccal administration)
Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.75 mL pre-filled syringe ; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.75 mL pre-filled syringe ; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
Historique des statuts LME
Sexe
Tous
Âge
Aussi recommandé pour les enfants
Équivalence thérapeutique
La recommandation concerne ce médicament spécifique
Renseignements sur le brevet
Patents have expired in most jurisdictions
Lire la suite
sur les brevets.
Résumé des preuves et recommandation du comité d'experts
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended amendments to the listing for midazolam for status epilepticus on the EML and EMLc to better describe the available dosage forms.